The head of UNAIDS maintained that Gilead could bring the AIDS pandemic toward an end if the company opens up access to lenacapavir
The head of UNAIDS maintained that Gilead could bring the AIDS pandemic toward an end if the company opens up access to its game-changing new HIV drug, Agence France Presse reports
The head of UNAIDS, Winnie Byanyima, urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat HIV patients. She urged Gilead to open up Lenacapavir to the UN-backed Medicines Patent Pool international organization so that cheaper generic versions could be sold under licenses in low- and middle-income nations.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins